"Bio Farma is honored that GPEI-WHO have trusted us to develop the vaccine. We are committed to support the program in order to anticipate the potential outbreak of wild poliovirus type 2 on global scale," stated Marketing Director of Bio Farma, Sri Harsi Teteki.
To followup this program, Bio Farma collaborate with UNICEF Supply Division based in Copenhagen, Denmark, to discuss the procurement of 60 million doses or 3 million vials throughout 2019.
To realize the mOPV type 2 global stockpiling, WHO has appointed a number of world's leading vaccine developpers, including Bio Farma, to make sure the procurement and stockpiling of the vaccine.
For the first stage, Bio Farma is required to produce and stockpile the 60 million doses or 3 million vials type 2 of mOPV-2 end products. These products must be available from June until August 2019.
"As the biggest vaccine producer in Southeast Asia, we are responsible to support the global polio eradication program. Sadly, the outbreak has recently occured in five African countries; Nigeria, Congo, Somalia, Kenya, and Ethiopia," concluded Sri.